Lois M. Mulligan focuses on Cancer research, RET proto-oncogene, Germline mutation, Multiple endocrine neoplasia and Genetics. Her Cancer research research is multidisciplinary, relying on both Missense mutation, Endocrine cancer, Carcinogenesis, Tumor suppressor gene and Point mutation. The RET proto-oncogene study combines topics in areas such as Receptor tyrosine kinase, Multiple endocrine neoplasia type 2, Mutation and Multiple endocrine neoplasia type 2b.
Her Multiple endocrine neoplasia type 2 research is multidisciplinary, incorporating perspectives in Internal medicine, Proto-Oncogene Proteins c-ret and Endocrinology. Her study in Germline mutation is interdisciplinary in nature, drawing from both Pheochromocytoma, Thyroid carcinoma and Germline. Her biological study spans a wide range of topics, including Mutation and Medullary carcinoma.
Lois M. Mulligan mostly deals with Genetics, Cancer research, RET proto-oncogene, Multiple endocrine neoplasia type 2 and Internal medicine. The study incorporates disciplines such as Germline mutation, Carcinogenesis, Receptor tyrosine kinase, Multiple endocrine neoplasia and Proto-Oncogene Proteins c-ret in addition to Cancer research. Her Germline mutation study integrates concerns from other disciplines, such as Medullary carcinoma, Thyroid carcinoma, Germline and Pathology.
Her RET proto-oncogene research incorporates themes from Neural crest, Mutation, Point mutation and Multiple endocrine neoplasia type 2b. Her Multiple endocrine neoplasia type 2 research integrates issues from Pheochromocytoma and Oncogene RET. Her studies deal with areas such as Endocrinology, Kinase and Oncology as well as Internal medicine.
Cell biology, Cancer research, Receptor tyrosine kinase, Glial cell line-derived neurotrophic factor and Receptor are her primary areas of study. Her work deals with themes such as Endocrinology, Internal medicine and Internalization, which intersect with Cell biology. Her Endocrinology research incorporates elements of Mutation, Germline mutation, Frameshift mutation and Germline.
Her research on Internal medicine frequently connects to adjacent areas such as Multiple endocrine neoplasia type 2. Her Cancer research research is multidisciplinary, incorporating elements of Neurotrophic factors, Lung cancer and Cell signaling. Her Receptor study combines topics in areas such as Function, Kinase, Kinase activity, RET proto-oncogene and Protein kinase domain.
Her scientific interests lie mostly in Cancer research, Cell biology, Receptor tyrosine kinase, Cell signaling and Cell. Her Cancer research research is multidisciplinary, incorporating elements of Mutation, Germline mutation, Cancer and Endocrinology. Her Cell signaling study also includes
The study incorporates disciplines such as Mesenchymal stem cell, Gene knockdown and Cell growth in addition to Cell. Lois M. Mulligan has included themes like Missense mutation, Gene, RET proto-oncogene and Kinase activity in her Receptor study. Her Medullary thyroid cancer research is multidisciplinary, incorporating perspectives in Multiple endocrine neoplasia type 2, Germline, Proto-Oncogene Proteins c-ret and Frameshift mutation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Lois M. Mulligan;John B. J. Kwok;Catherine S. Healey;Mark J. Elsdon.
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
Charis Eng;Charis Eng;David Clayton;Isabelle Schuffenecker;Gilbert Lenoir.
Mutations of the RET proto-oncogene in Hirschsprung's disease
Patrick Edery;Stanislas Lyonnet;Lois M. Mulligan;Anna Pelet.
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
Lois M. Mulligan;Lois M. Mulligan;Charis Eng;Catherine S. Healey;David Clayton.
Nature Genetics (1994)
Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours
C Eng;D P Smith;L M Mulligan;M A Nagai.
Human Molecular Genetics (1994)
Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast
Aurel Perren;Liang Ping Weng;Alexander H. Boag;Ulricke Ziebold.
American Journal of Pathology (1999)
Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease
Tania Attié;Anna Pelet;Patrick Edery;Charis Eng;Charis Eng.
Human Molecular Genetics (1995)
RET revisited: expanding the oncogenic portfolio
Lois M. Mulligan.
Nature Reviews Cancer (2014)
Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene
Lois M. Mulligan;Charts Eng;Tanla Attlé;Stanislas Lyonnet.
Human Molecular Genetics (1994)
Mechanisms of p53 loss in human sarcomas.
Lois M. Mulligan;Greg J. Matlashewski;Heidi J. Scrable;Webster K. Cavenee.
Proceedings of the National Academy of Sciences of the United States of America (1990)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: